Viegas FPD

References (1)

Title : New multifunctional AChE inhibitor drug prototypes protect against Abeta-induced memory deficit - Bellozi_2020_Neurol.Sci_41_451
Author(s) : Bellozi PMQ , Campos AC , Viegas FPD , Silva MF , Machado RP , Vaz SM , Riquiel MM , Carneiro-Junior WO , Lima IVA , Saliba SW , Vaz GN , Viegas C, Jr. , de Oliveira ACP
Ref : Neurol Sci , 41 :451 , 2020
Abstract : Alzheimer's disease (AD) is the most incident neurodegenerative disorder, characterized by accumulation of extracellular amyloid-beta (Abeta), intracellular neurofibrillary tangles, and cognitive impairment. The current available treatments are mainly based on the use of reversible acetylcholinesterase (AChE) inhibitors, which only ameliorate the cognitive deficits. However, it is important to develop disease-modifying drugs with neuroprotective effects in order to hamper the progression of the disease. Here, we describe the effect of four promising new drugs with additional protective characteristics on AD-associated memory changes. C57Bl/6 mice treated with the compounds received an intra-hippocampal injection of Abeta1-40 and were submitted to the novel object recognition test, to evaluate memory recovery. All the compounds prevented memory loss. Compounds PQM-56 (4c) and PQM-67 (4g) showed the best profile of memory recovery, representing potential drug candidates for AD treatment.
ESTHER : Bellozi_2020_Neurol.Sci_41_451
PubMedSearch : Bellozi_2020_Neurol.Sci_41_451
PubMedID: 31506829